Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.

@article{Doggrell2005PegaptanibTF,
  title={Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.},
  author={Sheila A Doggrell},
  journal={Expert opinion on pharmacotherapy},
  year={2005},
  volume={6 8},
  pages={1421-3}
}
Age-related macular degeneration is the leading cause of irreversible visual loss in the industrialised world. Angiogenesis underlies the neovascularisation, and vascular endothelial growth factor (VEGF) is an angiogenesis growth factor. In the VEGF Inhibition Study in Ocular Neovascularisation-1 (VISION-1) trial, pegaptanib (an aptamer inhibitor of VEGF) was tested in neovascular age-related macular degeneration. The 1186 patients received a sham injection or intravitreous injection of… CONTINUE READING